Health‐related quality of life in long‐term survivors with localised prostate cancer by therapy—Results from a population‐based study

Adam, Salome; Bertram, Heike; Eberle, Andrea; Holleczek, Bernd; Pritzkuleit, Ron; Waldeyer-Sauerland, Mechthild; Waldmann, Annika; Zeißig, Sylke Ruth; Rohrmann, Sabine; Brenner, Hermann; Arndt, Volker

doi:10.1111/ecc.13076

Cited by 20 publications

(18 citation statements)

References 37 publications

(75 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, patients who received ADT experienced greater burden over time. This is consistent with previous studies suggesting the diminished quality of life in patients who have been treated with ADT (12)(13)(14). What is surprising is that the self-reported burden in ADT cohort extended beyond the time frame in which testosterone recovery occurs (15,16).…”

Section: Discussionsupporting

confidence: 90%

Self-Reported Burden in Elderly Patients With Localized Prostate Cancer Treated With Stereotactic Body Radiation Therapy (SBRT)

et al. 2020

View full text Add to dashboard Cite

Retaining quality of life in patients treated with SBRT for prostate cancer remains paramount. As such, balancing the benefits of treatment against the effects of therapy on elderly patients is essential. The EORTC QLQ-ELD14 (ELD-14) is a validated questionnaire with a domain dedicated to burden of illness and treatment in the elderly. The Expanded Prostate Cancer Index Composite (EPIC)-26 is a validated questionnaire which measures urinary, bowel, sexual, and hormonal symptoms. This study reports trends in self-reported burden in patients with prostate cancer treated with SBRT and reveals convergence of self-reported burden with treatment related side effects obtained from the EPIC-26 questionnaire. Methods: All patients ≥70 years old, with localized prostate cancer treated with SBRT ± ADT at Medstar Georgetown University Hospital from 2013 to 2018 and had completed the ELD-14 were eligible for inclusion in this cross-sectional cohort study. Percentage of responses to questions related to disease and treatment burden were counted for each category ("not at all" and "a little" vs. "quite a bit" and "very much"). Additional demographic features were derived from available medical records. A total of 111 patients (median age of 74) responded to the ELD-14 questionnaire at onset of treatment and at the 2-year mark. Responses to EPIC questionnaires at matched follow-ups were scored and correlated with the self-reported burden domain of the ELD-14 using the Spearman correlation coefficient. Results: Number of patients reporting "quite a bit" or "very much" burden from prostate cancer was 6.3% prior to treatment. This was highest at 1-month (10.8%) and decreased to 9.0% at 24 months post-SBRT (X 2 = 3.836, p = 0.6986). By comparison, 3.6 and 5.4% reported "quite a bit" or "very much" burden from treatment at start of treatment and 24 months, respectively (X 2 =1.046, p = 0.9838). Patient reported treatment burden was found to converge well with individual domains of EPIC-26. Patients undergoing ADT experienced more burden than their non-ADT counterparts. Aghdam et al. Treatment Burden From Prostate SBRT Conclusions: This cross-sectional study suggests a minority of patients reported high burden from their clinically localized prostate cancer or from their SBRT treatment. Self-reported burden converged well with lower EPIC scores in multiple domains.

show abstract

Section: Discussionsupporting

confidence: 90%

Self-Reported Burden in Elderly Patients With Localized Prostate Cancer Treated With Stereotactic Body Radiation Therapy (SBRT)

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Proportion of long-term bowel dysfunction as evaluated by the EPIC questionnaire was higher in the EBRT group [1], while no difference between subgroups was observed in our study. In the CAESAR+ study [31], patients treated with RP or EBRT reported better QoL than patients receiving combined treatments, while two other studies showed that global QoL did not significantly differ in the long-term, irrespective of treatment [29,32]. Two other studies have also looked at the long-term sequelae of the management of PCa.…”

Section: Discussionmentioning

confidence: 99%

Impact on quality of life 3 years after diagnosis of prostate cancer patients below 75 at diagnosis: an observational case-control study

et al. 2020

View full text Add to dashboard Cite

Background: Prostate cancer patients are known to suffer from poor sexual and urinary long-term side-effects following treatment, potentially impacting quality of life. The purpose of our study was to compare health-related quality of life at 3 years between prostate cancer patients and healthy controls according to key lifestyle characteristics. Secondary objectives were to compare urological dysfunction, sexual function, anxiety and depression. Methods: Multicentric, case-control, observational prospective, open, follow-up study including 819 prostate cancer patients < 75 years old from the EPICAP cohort, newly diagnosed from 1 December 2011 to 31 March 2014 and 879 healthy controls. Participants were excluded if they experienced a relapse. Controls from the same geographical region were age-matched and were excluded if they were diagnosed with prostate cancer. Patients received one of the following treatments: active surveillance (AS), radical prostatectomy (RP), external beam radiotherapy (EBRT), High-intensity Focused Ultrasound (HIFU), chemotherapy (CT), or androgen deprivation therapy (ADT) as appropriate. The primary outcome was the quality of life as evaluated by the QLQ-C30 questionnaire. Scores were analyzed by multivariate analysis to adjust for predefined socio-demographic confounding effects. Results: In total, 564 participants were included (mean age 67.9 years): 376 patients and 188 controls. Treatment breakdown was: 258 underwent RP, 90 received EBRT, 52 brachytherapy or HIFU, 15 CT, 26 ADT and 61 AS. There was no difference in median global quality of life between patients and controls (94.87 vs 94.15, p = 0.71). Multivariate analysis showed poorer social functioning in patients (24.3% vs. 16.3%, p = 0.0209), more dyspnea (22% vs. 12.4%, p = 0.0078), and yet less current pain (23% vs 33%, p = 0.0151).

show abstract

“…According to the literature, patient-reported treatment-related long-term AEs are more frequent and more severe in patients who in addition to RP have undergone post-RP RAD [5][6][7][8][9][10][11][12][13]. The impact of post-treatment changes of dysfunctions/problems since the pre-RP situation on HRQoL, assessed by validated patient-completed questionnaires is, however, relatively uncertain, and more research on this field is needed.…”

Section: Introductionmentioning

confidence: 99%

Prostatectomy with or without post-operative radiotherapy: long-term adverse effects and quality of life

Monsen

Fosså

Dahl

et al. 2020

Scandinavian Journal of Urology

View full text Add to dashboard Cite

Health‐related quality of life in long‐term survivors with localised prostate cancer by therapy—Results from a population‐based study

Cited by 20 publications

References 37 publications

Self-Reported Burden in Elderly Patients With Localized Prostate Cancer Treated With Stereotactic Body Radiation Therapy (SBRT)

Self-Reported Burden in Elderly Patients With Localized Prostate Cancer Treated With Stereotactic Body Radiation Therapy (SBRT)

Impact on quality of life 3 years after diagnosis of prostate cancer patients below 75 at diagnosis: an observational case-control study

Prostatectomy with or without post-operative radiotherapy: long-term adverse effects and quality of life

Contact Info

Product

Resources

About